08/08/2025
Practice statement Re: Mounjaro
A new weight-loss treatment, Mounjaro (tirzepatide), is being introduced on the NHS to support individuals living with obesity. It will join the existing range of injectable medications, including Wegovy (semaglutide) and Saxenda (liraglutide).
Although NHS England has approved the drug, all GPs are waiting for information about how the drug will be provided to eligible patients, when, and for how long. The NHS in North West London (NWL) are developing plans to be able to make this available to suitable people who meet specific clinical criteria to enable an NHS health professional to prescribe it.
While NHS NWL are in the process of developing these plans, we ask patients not to contact the practice to request a prescription. GP Practices in NWL are not
In the meantime a range of weight loss support services are available to support you with weight management, if you would like to discuss other weight loss medications with a clinician please complete an online consultation request. Information about weight management services available can be found here: Lose weight | CVD
NHS England Guidance and Criteria.
NHS England has set the criteria eligibility for the drug, which will be rolled out in Phases; this is national policy, which, all NHS prescribers are required to abide by. For the First Cohort (during 2025-2026), NHS England estimates that only 222,000 patients across the whole of the UK will be eligible for the injection.
In 2026 and beyond there will be gradually broadening of those eligible on the NHS, see:
PRN01879-interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-NICE-fu.pdf for the full NHS England guidance
Once approved in NWL, to be able to have Mounjaro prescribed by your GP, you will need a BMI of over 40 with the four of the five following conditions:
1. Diagnosed hypertension
2. Diagnosed sleep apnoea
3. Diagnosed type 2 diabetes
4. Diagnosed cardiovascular disease
5. Diagnosed hypercholesterolemia.
If you do not meet these criteria, we cannot prescribe for you (based on the current guidance).